This is a pre-commercialization awareness effort ahead of potential FDA approval of QTORIN™ rapamycin. Traders should monitor upcoming clinical trial data (e.g., TOIVA study) and regulatory milestones as potential catalysts. Insider buying in the past 30 days may signal confidence in future developments.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 10 $142.11entry
- T+1 · 8mo ago −1.70%α −1.60% · $139.69
- T+5 · 8mo ago −15.00%α −14.09% · $120.80
- T+20 · 7mo ago −13.33%α −13.17% · $123.17
- T+60 · 6mo ago −18.78%α −30.46% · $115.42
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Palvella Therapeutics launched the 'BEYOND mLM' disease awareness campaign and website (BEYONDmLM.com) to educate patients, caregivers, and healthcare providers about microcystic lymphatic malformations (microcystic LMs), a rare and debilitating condition with no FDA-approved therapies. The campaign was developed in collaboration with leading nonprofit organizations and clinical experts in the vascular anomalies community.
Key Facts
- Palvella launched BEYONDmLM.com, an educational campaign and website focused on microcystic lymphatic malformations (microcystic LMs).
- The campaign was developed in partnership with five key nonprofit organizations: CaNVAS, LGDA, LE&RN, PeDRA, and VAccess.org.
- Microcystic LMs affect over 30,000 diagnosed patients in the U.S. and are characterized by malformed lymphatic vessels causing chronic leakage, bleeding, and recurrent infections.
- There are currently no FDA-approved treatments for microcystic LMs.
- Palvella’s lead investigational product, QTORIN™ rapamycin gel, is in development for this condition.
Financial Impact
No direct financial impact disclosed; campaign is educational and awareness-focused.
Risk Factors
- No guarantee that increased awareness will translate into future product adoption.
- QTORIN™ rapamycin remains investigational and may not achieve regulatory approval or commercial success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252673 |
Track record
36 reports on PVLA
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +35.07% at T+60 after the May 15, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 Now $144.60 −0.42% settles Dec 16
- Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 Now $144.60 −11.80% settles Dec 10
- Nov 5, 202611d ago 8-K Bullish 7/10 Entry $156.85 Now $144.60 −7.81% settles Dec 4
- Nov 5, 202611d ago Press Release Neutral 6/10 No price data
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 Now $144.60 −5.45% settles Dec 2
- Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 Now $144.60 +14.55% settles Nov 23
- Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 Now $144.60 +13.55% ▲ +20.29% +22.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers